204 related articles for article (PubMed ID: 20981688)
1. KIR receptor-ligand incompatibility predicts killing of osteosarcoma cell lines by allogeneic NK cells.
Delgado D; Webster DE; DeSantes KB; Durkin ET; Shaaban AF
Pediatr Blood Cancer; 2010 Dec; 55(7):1300-5. PubMed ID: 20981688
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
3. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
4. Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch.
Vampa ML; Norman PJ; Burnapp L; Vaughan RW; Sacks SH; Wong W
Transplantation; 2003 Oct; 76(8):1220-8. PubMed ID: 14578757
[TBL] [Abstract][Full Text] [Related]
5. Killer Ig-like receptor ligand mismatch directs NK cell expansion in vitro.
Rose MJ; Brooks AG; Stewart LA; Nguyen TH; Schwarer AP
J Immunol; 2009 Oct; 183(7):4502-8. PubMed ID: 19748981
[TBL] [Abstract][Full Text] [Related]
6. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
7. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
8. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells.
Markel G; Seidman R; Besser MJ; Zabari N; Ortenberg R; Shapira R; Treves AJ; Loewenthal R; Orenstein A; Nagler A; Schachter J
PLoS One; 2009; 4(5):e5597. PubMed ID: 19440333
[TBL] [Abstract][Full Text] [Related]
9. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.
Beelen DW; Ottinger HD; Ferencik S; Elmaagacli AH; Peceny R; Trenschel R; Grosse-Wilde H
Blood; 2005 Mar; 105(6):2594-600. PubMed ID: 15536148
[TBL] [Abstract][Full Text] [Related]
10. Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.
Nowak J; Kościńska K; Mika-Witkowska R; Rogatko-Koroś M; Mizia S; Jaskuła E; Polak M; Mordak-Domagała M; Lange J; Gronkowska A; Jędrzejczak WW; Kyrcz-Krzemień S; Markiewicz M; Dzierżak-Mietła M; Tomaszewska A; Nasiłowska-Adamska B; Szczepiński A; Hałaburda K; Hellmann A; Czyż A; Gil L; Komarnicki M; Wachowiak J; Barańska M; Kowalczyk J; Drabko K; Goździk J; Wysoczańska B; Bogunia-Kubik K; Graczyk-Pol E; Witkowska A; Marosz-Rudnicka A; Nestorowicz K; Dziopa J; Szlendak U; Warzocha K; Lange A;
Biol Blood Marrow Transplant; 2015 May; 21(5):829-39. PubMed ID: 25617806
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).
Purdy AK; Campbell KS
Cancer Biol Ther; 2009 Dec; 8(23):2211-20. PubMed ID: 19923897
[TBL] [Abstract][Full Text] [Related]
12. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis.
Kubista B; Trieb K; Blahovec H; Kotz R; Micksche M
Anticancer Res; 2002; 22(2A):789-92. PubMed ID: 12014651
[TBL] [Abstract][Full Text] [Related]
14. Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.
Freund J; May RM; Yang E; Li H; McCullen M; Zhang B; Lenvik T; Cichocki F; Anderson SK; Kambayashi T
PLoS Biol; 2016 Aug; 14(8):e1002526. PubMed ID: 27500644
[TBL] [Abstract][Full Text] [Related]
15. NK cell killer Ig-like receptor repertoire acquisition and maturation are strongly modulated by HLA class I molecules.
Sleiman M; Brons NH; Kaoma T; Dogu F; Villa-Forte A; Lenoble P; Hentges F; Kotsch K; Gadola SD; Vilches C; Zimmer J
J Immunol; 2014 Mar; 192(6):2602-10. PubMed ID: 24554773
[TBL] [Abstract][Full Text] [Related]
16. Analysis of KIR ligand incompatibility in human renal transplantation.
Tran TH; Mytilineos J; Scherer S; Laux G; Middleton D; Opelz G
Transplantation; 2005 Oct; 80(8):1121-3. PubMed ID: 16278595
[TBL] [Abstract][Full Text] [Related]
17. Rapid, flow cytometric assay for NK alloreactivity reveals exceptions to rules governing alloreactivity.
De Santis D; Foley BA; John E; Senitzer D; Christiansen FT; Witt CS
Biol Blood Marrow Transplant; 2010 Feb; 16(2):179-91. PubMed ID: 19879950
[TBL] [Abstract][Full Text] [Related]
18. Homogenous expression of killer cell immunoglobulin-like receptors (KIR) on polyclonal natural killer cells detected by a monoclonal antibody to KIR2D.
Watzl C; Peterson M; Long EO
Tissue Antigens; 2000 Sep; 56(3):240-7. PubMed ID: 11034560
[TBL] [Abstract][Full Text] [Related]
19. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
Wang W; Erbe AK; Alderson KA; Phillips E; Gallenberger M; Gan J; Campana D; Hank JA; Sondel PM
Cancer Immunol Immunother; 2016 Sep; 65(9):1047-59. PubMed ID: 27392940
[TBL] [Abstract][Full Text] [Related]
20. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation.
Yu J; Venstrom JM; Liu XR; Pring J; Hasan RS; O'Reilly RJ; Hsu KC
Blood; 2009 Apr; 113(16):3875-84. PubMed ID: 19179302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
